Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, T., Wolf, T., Schleicher, J., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2018.

Oncol Res Treat 41 (suppl4)(P602), 201-202.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2018
705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal:
NABUCCO
2018
Molekulare Testung, Häufigkeiten molekularer Alterationen und zielgerichtete Erstlinientherapie bei Patienten mit Nicht-kleinzelligem Lungenkarzinom in Deutschland. Ergebnisse der prospektiven Registerplattform CRISP (AIO-TRK-0315).

Griesinger F.; Eberhardt W.; Nusch A.; Reiser M.; Bernhardt C.; Marschner N.; Jänicke M.; Fleitz A.; Spring L.; Sahlmann J.; Karatas A.; Hipper A.; Weichert W.; Rittmeyer A.; Bischoff H.; Waller C.F.; Sebastian M.; Thomas M.; 2018.

Oncol Res Treat 2018;41(suppl 4):1–358

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2018
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: BMC Cancer
REASON
2018
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel, S., Steffens, C.-C., Meyer, D., Tesch, H., Kruggel, L., Frank, M., Jänicke, M., Marschner, M. 2017.

Breast Cancer, 4 December 2017, 1–9. https://doi.org/10.1007/s12282-017-0823-7.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer
TMK
2017
Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Losem, C., Ketzler-Henkel, Zahn, M., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., deWit, M., Metzenmacher, M., Waller, C., Kern, J., Weichert, W., Sebastian, M., Thomas, M., 2017.

IASLC World Conference (Yokohama) (P3.01-088).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: IASLC (WCLC) / Journal: -
CRISP
2017
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Schirmacher, P., Sebastian, M., Thomas, M., 2017.

7th European Lung Cancer Conference (ELCC) (125P).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ELCC (IASLC) / Journal: -
CRISP
2017
Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer – results from the prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P600), 174.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2017
Treatment reality and outcome data of patients with advanced papillary cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Goebell, P., Müller, L., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P339), 96.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2017
Systemic palliativ treatment and outcome in later lines in patients with metastatic colorectal cancer – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Schnell, R., Uhlig, J., Eggers, E., Jänicke, M., Fleitz, A., Wetzel, N., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P587).

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2017